Prot #CC-122-DLBCL-001: A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date9/17/139/17/19

Funding

  • Celgene Corporation (Prot #CC-122-DLBCL-001)